Zizant 3MIU Injection contains Colistimethate Sodium equivalent to 3 million International Units (IU) and is indicated for the treatment of serious infections caused by susceptible strains of Gram-negative bacteria, including multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Colistimethate Sodium is a polymyxin antibiotic that acts by disrupting the bacterial cell membrane, leading to cell death. This injectable formulation is primarily used in severe systemic infections such as ventilator-associated pneumonia, bloodstream infections, and complicated urinary tract infections when alternative antibiotics are ineffective or contraindicated. Zizant 3MIU Injection should be administered intravenously under strict medical supervision, with dosage adjusted based on the severity of infection, renal function, and patient response. Monitoring of renal function and neurological status is essential during therapy due to potential nephrotoxicity and neurotoxicity associated with colistin use. The injection must be reconstituted and diluted according to manufacturer guidelines to ensure stability and efficacy. Zizant 3MIU Injection is contraindicated in patients with known hypersensitivity to polymyxins. Its use should be guided by culture and sensitivity results to optimize therapeutic outcomes and minimize resistance development.